5 active not recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
Follow Recurrent Peripheral Primitive Neuroectodermal Tumor: new trials by email Literature Review of Recurrent Peripheral Primitive Neuroectodermal Tumor trials Research Report on Recurrent Peripheral Primitive Neuroectodermal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
Ependymoma (5) · Glioma (5) · Hepatoblastoma (5) · Histiocytosis, Langerhans-Cell (5) · Lymphoma, Non-Hodgkin (5) · Medulloblastoma (5) · Neuroblastoma (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Osteosarcoma (5) · Rhabdoid Tumor (5) · Rhabdomyosarcoma (5) · Sarcoma (5) · Sarcoma, Ewing (5) · Wilms Tumor (5) · Central Nervous System Neoplasms (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genetic Diseases, Inborn (5) · Hemic and Lymphatic Diseases (5) · Histiocytosis (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Kidney Diseases (5) · Kidney Neoplasms (5) · Lung Diseases (5) · Lung Diseases, Interstitial (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Male Urogenital Diseases (5)
Magnetic Resonance Spectroscopy (2) · Nuclear Medicine Department, Hospital (2) · Phantoms, Imaging (2) · X-Rays (2) · ivosidenib (2) · selpercatinib (2) · tipifarnib (2) · ulixertinib (2) · Biopsy (1) · LY3023414 (1) · Pharmacogenomic Variants (1) · Specimen Handling (1) · Vemurafenib (1) · ensartinib (1) · erdafitinib (1)
National Cancer Institute (NCI) (5)
Puerto Rico (5) · United States (5) · Australia (3) · Canada (1)
Andrea T Franson (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Kieuhoa T Vo (1)
PMID 31401903, PMID 33591402, PMID 35353553, PMID 38935895, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (5)